PEARSON PHARMA PARTNERS:1198214 [16-013035]IGF::CL::IGF

每份咨询合同将针对本工作说明书中概述的一个或多个专业领域，并将反映NIH对特定专业领域的时间承诺需求。 根据这一要求聘请的顾问不仅将为通过严格的同行评审过程选择的有前途的药物发现和开发项目做出重大贡献，他们还将帮助塑造一个创新的，备受瞩目的项目，该项目可能成为未来NIH药物发现工作的典范。 合同顾问将通过电话会议和电子邮件向NIH和BPN LDT成员提供有关计划和项目的反馈和指导。顾问可临时担任或作为最不发达国家小组的成员。预计顾问将就项目里程碑、开发战略、研究设计和数据解释提供投入。具体的咨询责任将取决于个别顾问的专业知识和个别项目和计划的需要。 BPN目前有处于探索性到临床前安全性阶段的项目。部分项目将进入新药研究（IND）和临床试验阶段。项目的延续将取决于具体项目里程碑的实现和项目组合的管理。自2011年以来，有15个项目进入了业务方案网络，5个项目仍在进行中。新项目每年审查两次，得分最高的项目可能会纳入该计划。

Each consulting contract will be specific to one or more areas of expertise as outlined in this Statement of Work, and will reflect the NIH time commitment needs for the specific areas of expertise. Consultants hired under this requirement will not only make significant contributions to promising drug discovery and development projects that have been selected through a rigorous peer-review process, they will also help shape an innovative, high-profile program that may serve as a model for future NIH drug discovery efforts. Contract consultants will be expected to provide feedback and guidance on programs and projects to the NIH and to BPN LDT members through conference calls and by email. Consultants may serve on an ad hoc basis or as members of LDTs. Consultants will be expected to offer input on project milestones, development strategy, study design, and data interpretation. Specific consulting responsibilities will depend on the expertise of the individual consultant and the needs of individual projects and programs. The BPN currently has projects in the exploratory through preclinical safety stages. Some projects will proceed to the Investigational New Drug (IND) and clinical trial stages. Project continuation will depend on the achievement of project-specific milestones and portfolio management. Since 2011, fifteen projects have entered the BPN, and five projects remain active. New projects are reviewed twice per year and the highest scoring projects may be incorporated into the program.